Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 5/20 | 0.63 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.63 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.63 |
| ▸ | GUSB | P08236 | 11/20 | 0.58 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28646510 | 0.86 | TNKS (0.67) | TNKSTNKS2CYP1A1CYP1B1GUSB | |
| SCHEMBL4712542 | 0.85 | PTGES (0.53) | TNKSTNKS2CYP1A1CYP1B1GUSB | |
| SCHEMBL4712040 | 0.84 | GUSB (0.68) | TNKSTNKS2CYP1A1CYP1B1GUSB | |
| SCHEMBL3512712 | 0.81 | NPC1 (0.67) | KDM4EHPGDALDH1A1MAPTHSD17B10 | |
| SCHEMBL802560 | 0.78 | GUSB (0.68) | TNKSTNKS2CYP1A1CYP1B1GUSB | |
| SCHEMBL29784068 | 0.78 | TNKS (1.00) | TNKSTNKS2CYP1A1CYP1B1GUSB | |
| SCHEMBL5795292 | 0.78 | TNKS (1.00) | TNKSTNKS2CYP1A1CYP1B1GUSB | |
| SCHEMBL17904243 | 0.77 | TNKS (0.71) | TNKSTNKS2CYP1A1CYP1B1GUSB | |
| SCHEMBL3110381 | 0.77 | TNKS (0.62) | TNKSTNKS2CYP1A1CYP1B1GUSB | |
| SCHEMBL6695759 | 0.77 | TNKS2 (0.81) | TNKSTNKS2CYP1A1CYP1B1GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951075-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-24 | — | — | US | disclosed |
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciencies Ireland UC (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciencies Ireland UC (IE) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | HCCS, HAVCR2, MAVS | TNKS 355/4885TNKS2 892/4885CYP1A1 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.